136 related articles for article (PubMed ID: 30214522)
1. Overexpression of TRIM44 is an independent marker for predicting poor prognosis in epithelial ovarian cancer.
Liu S; Yin H; Ji H; Zhu J; Ma R
Exp Ther Med; 2018 Oct; 16(4):3034-3040. PubMed ID: 30214522
[TBL] [Abstract][Full Text] [Related]
2. High TRIM44 expression as a valuable biomarker for diagnosis and prognosis in cervical cancer.
Liu S; Meng F; Ding J; Ji H; Lin M; Zhu J; Ma R
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30792262
[TBL] [Abstract][Full Text] [Related]
3. High TRIM44 expression in endometrial carcinoma is associated with a poorer patient outcome.
Li P; Yin H; Meng F; Liu S; Liu H; Ma R
Pathol Res Pract; 2018 May; 214(5):727-731. PubMed ID: 29526558
[TBL] [Abstract][Full Text] [Related]
4. Correlation between tripartite motif-containing protein 44 protein expression and the prognosis of postoperative patients exhibiting skin squamous cell carcinoma.
Wu J; Guo NZ; Cui LL; Wang W; Xiong CQ; Zhang XY
Medicine (Baltimore); 2018 Nov; 97(44):e13021. PubMed ID: 30383661
[TBL] [Abstract][Full Text] [Related]
5. Expression of tripartite motif-containing 44 and its prognostic and clinicopathological value in human malignancies:a meta-analysis.
Xiao G; Yang Q; Bao Z; Mao H; Zhang Y; Lin S
BMC Cancer; 2020 Jun; 20(1):525. PubMed ID: 32503466
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of
Meng F; Ding J; Xu W; Luo C; Chen X; Zhang R; Sui L; Hu Y; Liu S; Shi G; He Y; Ning X; Ma R; Huang N
Transl Cancer Res; 2022 Feb; 11(2):414-425. PubMed ID: 35281418
[TBL] [Abstract][Full Text] [Related]
7. Combined A20 and tripartite motif-containing 44 as poor prognostic factors for breast cancer patients of the Japanese population.
Sato J; Azuma K; Kinowaki K; Ikeda K; Ogura T; Takazawa Y; Kawabata H; Kitagawa M; Inoue S
Pathol Int; 2021 Jan; 71(1):60-69. PubMed ID: 33159706
[TBL] [Abstract][Full Text] [Related]
8. Variation and prognostic value of serum plasminogen activator inhibitor-1 before and after chemotherapy in patients with epithelial ovarian cancer.
Chen S; Tai H; Tong X; Wang J; Yang F; Yang Y; Yiqin O
J Obstet Gynaecol Res; 2014 Sep; 40(9):2058-65. PubMed ID: 25181626
[TBL] [Abstract][Full Text] [Related]
9. Low levels of ADAM23 expression in epithelial ovarian cancer are associated with poor survival.
Ma R; Tang Z; Sun K; Ye X; Cheng H; Chang X; Cui H
Pathol Res Pract; 2018 Aug; 214(8):1115-1122. PubMed ID: 29921495
[TBL] [Abstract][Full Text] [Related]
10. TRIM44 activates the AKT/mTOR signal pathway to induce melanoma progression by stabilizing TLR4.
Wei CY; Wang L; Zhu MX; Deng XY; Wang DH; Zhang SM; Ying JH; Yuan X; Wang Q; Xuan TF; He AQ; Qi FZ; Gu JY
J Exp Clin Cancer Res; 2019 Mar; 38(1):137. PubMed ID: 30922374
[TBL] [Abstract][Full Text] [Related]
11. Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling.
Peng R; Zhang PF; Zhang C; Huang XY; Ding YB; Deng B; Bai DS; Xu YP
Cancer Med; 2018 Mar; 7(3):796-808. PubMed ID: 29446253
[TBL] [Abstract][Full Text] [Related]
12. TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling.
Kawabata H; Azuma K; Ikeda K; Sugitani I; Kinowaki K; Fujii T; Osaki A; Saeki T; Horie-Inoue K; Inoue S
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885545
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of TRIM44 Expression in Patients with Gastric Cancer.
Goshayeshi L; Afshar J; Mehrad-Majd H
Asian Pac J Cancer Prev; 2022 May; 23(5):1725-1731. PubMed ID: 35633558
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of GPNMB predicts an unfavorable outcome of epithelial ovarian cancer.
Ma RQ; Tang ZJ; Ye X; Cheng HY; Sun KK; Chang XH; Cui H
Arch Gynecol Obstet; 2018 May; 297(5):1235-1244. PubMed ID: 29428978
[TBL] [Abstract][Full Text] [Related]
15. Clinical associations between ASCT2 and p‑mTOR in the pathogenesis and prognosis of epithelial ovarian cancer.
Guo H; Xu Y; Wang F; Shen Z; Tuo X; Qian H; Wang H; Wang K
Oncol Rep; 2018 Dec; 40(6):3725-3733. PubMed ID: 30272366
[TBL] [Abstract][Full Text] [Related]
16. MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer.
Liu L; Yi J; Deng X; Yuan J; Zhou B; Lin Z; Zeng Z
Oncol Lett; 2019 Aug; 18(2):1049-1056. PubMed ID: 31423165
[TBL] [Abstract][Full Text] [Related]
17. Expression of HPIP in epithelial ovarian carcinoma: a clinicopathological study.
Wang Y; Meng F; Liu Y; Chen X
Onco Targets Ther; 2017; 10():95-100. PubMed ID: 28053543
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of kinesin family member 20A is associated with unfavorable clinical outcome and tumor progression in epithelial ovarian cancer.
Li H; Zhang W; Sun X; Chen J; Li Y; Niu C; Xu B; Zhang Y
Cancer Manag Res; 2018; 10():3433-3450. PubMed ID: 30254487
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Siah2 Is Associated With Poor Prognosis in Patients With Epithelial Ovarian Carcinoma.
Gao Y; Liu Y; Meng F; Shang P; Wang S; Zhang Y; Sun Y; Wang Y; Wang J; Chen X
Int J Gynecol Cancer; 2016 Jan; 26(1):114-9. PubMed ID: 26512788
[TBL] [Abstract][Full Text] [Related]
20. Overexpression and clinical significance of IBP in epithelial ovarian carcinoma.
Xu Y; Hou Y; Liu T; Lou G
Oncol Lett; 2018 May; 15(5):6604-6610. PubMed ID: 29616123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
